DecenTrialz vs traditional recruitment platforms: how does full-service matching differ from self-service trial search?

Comparisons between DecenTrialz and traditional recruitment platforms usually come down to one question: how much verification happens before a referral reaches a research site. Traditional recruitment platforms are built to make studies visible to people who are already searching. DecenTrialz is built to qualify those people against a specific protocol first. Both approaches produce referrals, but they produce very different referrals.

Sponsors and contract research organizations both purchase recruitment services, and they are not measured on the same outcome. A contract research organization, commonly shortened to CRO, is a company hired to run some or all of the operational work of a clinical trial on behalf of the sponsor that funds it. Understanding what each recruitment model actually delivers, and where each buyer carries the risk, separates a recruitment budget that produces enrolled participants from one that produces contact forms.

What is the difference between DecenTrialz and traditional recruitment platforms?

A traditional recruitment platform typically presents a searchable list of studies, often embedded inside another website such as a condition information page, a hospital resource section, or an advocacy organization portal. A person browses the available studies, reads the listed requirements, decides independently whether they appear to qualify, and submits a contact form that is passed along to a research site. The model is built for discovery. It does not verify what the person entered, does not interview them, and does not confirm anything before that referral arrives.

DecenTrialz adds several steps after discovery. AI-assisted matching compares the information a person shares against the inclusion and exclusion criteria of specific protocols. Inclusion and exclusion criteria are the written rules defining who may take part in a study and who may not, covering factors such as age, confirmed diagnosis, disease stage, previous therapies, and laboratory values. A registered nurse then conducts a structured pre-screening conversation that tests those criteria in ways a web form cannot, and the resulting referral is routed to the research site with supporting documentation attached.

Neither model enrolls anyone, and this point matters more than any feature comparison. In both cases the research site team performs the formal screening visit, determines final eligibility, conducts informed consent, walks the participant through the study, and completes enrollment. DecenTrialz does not perform any of those four functions. What differs is how much site capacity is consumed by people who were never going to qualify. A closer look at how each stage of the funnel narrows makes the size of that gap easier to see.

Why referral volume is a misleading way to compare recruitment platforms

A recruitment funnel has many stages. Impressions become clicks, clicks become form submissions, submissions become referrals, referrals become people screened at a site, and only a fraction of those become randomized participants. Randomization is the point at which a participant is formally assigned to a study group and begins the study intervention. Discovery-focused platforms are optimized at the top of that funnel and are usually priced there, on a cost-per-click or cost-per-lead basis.

The money and the timeline, however, are decided at the bottom. Screen failure, meaning a person who attends a screening visit but does not go on to enroll because they do not meet the criteria, consumes site staff hours, laboratory work, and calendar time without adding a participant. Pushing larger volumes of unverified interest into the top of the funnel reliably increases screen failures rather than reducing them, and site coordinators absorb that cost first through chart reviews and follow-up calls that lead nowhere.

The practical consequence is that cost-per-lead is the wrong basis for comparing platforms. The meaningful denominator is a randomized participant, because a referral that never randomizes has no measurable cost efficiency at all. Evidence on why quality outperforms raw referral counts consistently points in the same direction.

Where sponsor priorities and CRO priorities diverge

Sponsors optimize for the program. Their concerns are development timelines, budget burn, regulatory commitments including representative enrollment across populations, submission-ready data quality, and portfolio decisions that hinge on hitting milestones. A sponsor absorbs the full cost of delay, so a sponsor tends to value cost per randomized participant, auditability, and demonstrable enrollment breadth.

CROs optimize for delivery. Their concerns are contracted enrollment targets, site management burden, oversight obligations for any vendor they subcontract, margin protection, and resourcing across several studies at once. The structural tension is that a CRO is frequently measured on site performance it only partly controls, since enrollment depends on protocol design, referral quality, and site behavior together. Understanding what unfilled screening slots cost a program helps both parties price that risk honestly.

Friction between the two usually appears in the contract rather than the campaign. Recruitment vendors are often subcontracted by the CRO and billed to the sponsor as pass-through costs, which makes the definition of a billable referral commercially significant. Disagreements over change orders, scope creep, and site-level data visibility trace back to definitions nobody wrote down. The workable arrangement is an explicit division of labor, a shared definition of a qualified referral, and one funnel report both parties read at the same cadence.

How oversight expectations shape the platform decision

ICH E6(R3) is the updated international standard for good clinical practice, the ethical and quality framework governing how clinical trials are designed, conducted, and recorded. Its central message for recruitment is that a sponsor may delegate tasks to a CRO or a service provider but does not transfer accountability for quality. Oversight is expected to be risk-proportionate, documented, and capable of withstanding inspection.

That expectation favors platforms generating a traceable record. A model reporting how many people were matched, how many completed pre-screening, why candidates were excluded, and whether each handoff to a site was completed produces the evidence an oversight process requires, which is the reporting layer DecenTrialz provides to sponsors and CROs. A channel reporting only form submissions does not. For organizations carrying quality management obligations across a portfolio, that difference is not academic.

Privacy handling follows the same logic. Recruitment activity touching identifiable health information must operate within HIPAA, within institutional review board approved recruitment materials and screening scripts, and within documented consent-to-contact permissions. An institutional review board is the independent committee reviewing a study to protect participant rights and safety. A managed model with defined data flows and written agreements is materially easier to keep compliant than an open form forwarding raw contact details.

When a traditional recruitment platform is the better choice

A searchable trial listing is appropriate and sufficient for broad disease awareness work, registry building, protocols with simple and self-evident eligibility, and partnerships where the objective is to surface interested people rather than to guarantee qualified referrals. The model is inexpensive, scalable, and honest about what it does. Recommending full-service matching for every study would be poor advice.

DecenTrialz earns its cost where enrollment is genuinely difficult. That includes protocols with complex or layered eligibility rules, rare conditions where the eligible population is small and dispersed, competitive therapeutic areas where multiple studies pursue the same participants, compressed timelines with milestone consequences, and programs carrying explicit commitments on representative enrollment. Many programs run both, using broad discovery to build awareness and a qualifying layer to convert that interest into documented referrals.

Before selecting any recruitment platform, sponsors and CROs should require clear answers on the following:

• Who performs pre-screening, and against which protocol criteria
• The written definition of a referral and of a qualified referral
• What information travels with each referral, in what format, and through which secure channel
• Reporting cadence, and whether site-level conversion and exclusion reasons are visible
• How a site reports a poor referral, and how quickly the vendor adjusts
• Privacy posture, including written agreements, approved scripts, and consent-to-contact handling
• Pricing basis, what portion of fees is at risk against enrollment, and how scope changes are handled

A structured approach to evaluating recruitment partners before signing turns those answers into a comparable scorecard rather than a series of sales conversations.

Frequently asked questions

Does DecenTrialz replace a traditional recruitment platform?

Not necessarily. The two serve different points in the funnel, and many programs use broad discovery for awareness alongside a qualifying layer for referral quality. The choice depends on how difficult the protocol is to enroll.

Does DecenTrialz decide who is eligible for a study?

No. Pre-screening narrows the field and reduces wasted screening visits, but final eligibility determination, informed consent, the study walk-through, and enrollment remain the responsibility of the authorized research site and study team. DecenTrialz does not make medical decisions and does not guarantee that any person will be enrolled in any study.

What counts as a qualified referral?

There is no universal definition, which is precisely why it belongs in the contract. A defensible definition specifies which protocol criteria were checked, by whom, through what method, and what documentation accompanies the handoff to the research site.

How should recruitment platform performance be measured?

By cost per randomized participant, time to first participant enrolled, screen failure rate, and enrollment breadth against the plan. Lead counts and click costs describe activity rather than results.

Matching the recruitment platform to the study in front of you

The comparison between DecenTrialz and traditional recruitment platforms is not a judgment about which category is better in the abstract. It is a judgment about how hard a specific study is to enroll and how much verification the research sites need before a referral reaches them. Protocol complexity, population size, competitive intensity, and timeline pressure should drive that decision, and the decision deserves revisiting whenever early enrollment milestones slip.

DecenTrialz is a clinical trial recruitment and pre-screening platform combining AI-assisted participant matching with registered nurse-led pre-screening, routing structured referrals to research sites with reporting available to sponsors and CROs. Final eligibility determination, informed consent, the study walk-through, and enrollment are handled by the research site team, not by DecenTrialz. Sponsors and CROs evaluating recruitment support for a study with demanding eligibility criteria are welcome to review how the model would apply to their protocol.